Mesoblast Limited (ASX:MSB) said that the Oncologic Drugs Advisory Committee of the US FDA had scheduled a meeting on 13 August 2020 for the review of data supporting MSB’s Biologics License Application for approval of RYONCIL™ (remestemcel-L) for the treatment of SR-aGVHD in children.
Moreover, RYONCIL is under Priority Review by the FDA with an action date of 30 September 2020, under the Prescription Drug User Fee Act.
Post announcement, MSB quoted at A$3.610 up by 7.761% at AEST 12:01 PM.
Penny stocks have been known to attract investors who are looking for explosive gains and it is possible to get lucky with these typically speculative investments. Just as the name suggests, penny stocks trade at low prices and are common shares of small public companies.
Get an exclusive insight into the features of penny stocks along with their pros and cons. Read about what you should be wary about when figuring out ways to invest in them, so that the possibility for big rewards does not tend to outweigh the risks.